2؉ mobilization in a variety of mammalian cells. However, the metabolism and actions of cADPR in the renal vasculature are poorly understood. In the present study, we characterized the enzymatic pathway of the production and metabolism of cADPR along the renal vascular tree and determined the role of cADPR in the control of intracellular [Ca 2؉ ] and vascular tone. The high performance liquid chromatographic analyses showed that cADPR was produced and hydrolyzed along the renal vasculature. The maximal conversion rate of nicotinamide guanine dinucleotide (NGD) into cyclic GDP-ribose (that represents ADP-ribosyl cyclase activity for cADPR formation) was 8.69 ؎ 2.39 nmol/min/mg protein in bulk-dissected intrarenal preglomerular vessels (n ‫؍‬ 7) and 4.35 ؎ 0.13, 2.23 ؎ 0.27, 2.40 ؎ 0.19, and 0.31 ؎ 0.02 nmol/min/mg protein, respectively, in microdissected arcuate arteries (n ‫؍‬ 6), interlobular arteries (n ‫؍‬ 6), afferent arterioles (n ‫؍‬ 7), and vasa recta (n ‫؍‬ 10). The activity of cADPR hydrolase was also detected in the renal vasculature. Using the fluorescence microscopic spectrometry, cADPR was found to produce a large rapid Ca 2؉ release from ␤-escin-permeabilized renal arterial smooth muscle cells (SMCs). In isolated, perfused, and pressurized small renal arteries, cADPR produced a concentration-dependent vasoconstriction when added into the bath solution. The vasoconstrictor effect of cADPR was completely blocked by tetracaine, a Ca 2؉ -induced Ca 2؉ release (CICR) inhibitor. These results suggest that an enzymatic pathway for cADPR production and metabolism is present along the renal vasculature and that cADPR may importantly contribute to the control of renal vascular tone through CICR.
INTRODUCTION
Cyclic ADP-ribose (cADPR) is an endogenous metabolite of nicotinamide adenine dinucleotide (NAD) via ADP-ribosyl cyclase (Galione, 1993; Lee, 1994; Lee et al., 1994) . cADPR was first reported to be present in sea urchin eggs and to possess Ca 2ϩ -mobilizing activity (Lee et al., 1989) . Recent studies have indicated that cADPR may be detected in a variety of mammalian tissues or cells such as heart, liver, spleen, brain tissues and red blood cells, lymphocytes, pituitary cells, and renal epithelial cells (Beer et al., 1995b; Koshiyama et al., 1991; Lee and Arthus, 1993; Takesawa et al., 1993; White et al., 1993) . Tissue concentrations of cADPR in cardiac muscle, liver, and brain have been estimated as 100 -200 nM (Galione, 1992; Lee et al., 1994) . The enzymes responsible for the synthesis and degrada-tion of this nucleotide have been characterized. In mammalian tissues, ADP-ribosyl cyclase is a membrane-bound enzyme. The reaction catalyzed by ADPribosyl cyclase does not require any exogenous cofactor (Lee, 1994) . The enzyme responsible for the hydrolysis of cADPR is also membrane-bound and present in a wide range of mammalian tissues. This cADPR hydrolase catalyzes the hydrolysis of cADPR to produce ADPR (Galione, 1993; Lee, 1994) .
It has been demonstrated that Aplysia ADP-ribosyl cyclase gene has 69% homology with human lymphocyte differentiate antigen CD38 (States et al., 1992) . Purified or recombinant human lymphocyte antigen CD38 protein and its mouse and rat homologue have been revealed to have both ADP-ribosyl cyclase and cADPR hydrolase activity (Howard et al., 1993; Koguma et al., 1994; Lee, 1994; Shubinsky and Schlesinger, 1997) . This membrane-bound CD38 protein has been considered as a multiple functional enzyme to serve as a molecular switch for regulating the cellular levels of cADPR in mammalian tissues. The cellular cADPR levels could be elevated or decreased by balancing the synthetic and hydrolytic activities of CD38, respectively (Lee, 1994; Lee et al., 1994) . Recent studies in our laboratory have demonstrated that this enzymatic pathway responsible for the production and metabolism of cADPR is present in coronary arterial smooth muscle cells and that tissue cADPR concentration in coronary arterial smooth muscle is about 150 nM (Geiger et al., 2000; Li et al., 1998) .
Cyclic ADPR produces intracellular Ca 2ϩ mobilization in a variety of tissues and cells by a mechanism completely independent of D-myo-inositol 1,4,5-triphosphate (IP 3 ), since IP 3 receptor antagonist, heparin can not block the effect of cADPR (Galione, 1993; Lee, 1994; Lee et al., 1994) . It has been found to activate ryanodine receptors on the sarcoplasmic or endoplasmic reticulum and result in Ca 2ϩ release (Galione, 1993; Lee et al., 1994) . There is increasing evidence indicating that cADPR serves as a second messenger to mediate the effects of a number of agonists to mobilize intracellular Ca 2ϩ in different tissues or cells. Studies using pancreatic ␤ cells strongly suggested that cADPR mediates glucose-induced insulin secretion (Takesawa et al., 1993) . cADPR may also mediate the effects of acetylcholine receptors in adrenal chromaffin cells, estrogen receptors on the uterus, 5-HT 2B receptor in arterial endothelial cells, and retinoic acid in renal tubular cells and aortic smooth muscle (Beers et al., 1995b; Chini et al., 1997 Chini et al., , 1995 Morita et al., 1997; Ullmer et al., 1996) .
In addition to these actions in mediating agonist responses, cADPR has been indicated to modulate Ca 2ϩ -induced Ca 2ϩ release (CICR), thereby regulating global Ca 2ϩ levels within the cells (Galione et al., 1991 (Galione et al., , 1998 Lee, 1993) . The sensitization of ryanodine receptors by cADPR plays an important role in excitationcontraction coupling in cardiac muscle and in coupling between Ca 2ϩ influx and intracellular Ca 2ϩ release in the neurons. This CICR is of importance in the control of vascular tone, since the entry of Ca 2ϩ through voltage-operating channels would produce a global Ca 2ϩ increase throughout the cytoplasma and nucleus by CICR and thereby lead to vasoconstriction (Berridge, 1994 (Berridge, , 1997 Galione et al., 1998) . cADPR may be involved in this amplification of intracellular Ca 2ϩ signal through CICR. However, this hypothesis has to be tested. The role of cADPR-mediated Ca 2ϩ signaling pathway in the control of vascular tone is poorly understood. The purpose of the present study was to characterize the enzymatic pathway of cADPR formation and metabolism in the renal vasculature, including renal pre-and postglomerular microvessels, using HPLC analysis and to examine the effect of cADPR on intracellular [Ca 2ϩ ] in renal arterial smooth muscle cells using fluorescent microscopic spectrometry. We also examined the effect of cADPR on the vascular tone using an isolated, perfused, and pressurized small renal arterial preparation and determined the contribution of CICR to cADPR-induced intracellular Ca 2ϩ release and vasoconstriction.
MATERIALS AND METHODS
Preparation of the homogenates from bulk-dissected intrarenal arteries. Small intrarenal arteries were dissected as we described previously (Zou et al., 1996a,b) . Briefly, Sprague-Dawley rats weighing between 250 and 300 g were anesthetized with sodium pentobarbital (80 mg/kg body wt., i.p.), and the kid-neys were flushed with physiological salt solution (PSS), which contains (mM): NaCl, 135; KCl, 3; CaCl 2 , 1.5; MgSO 4 , 1; KH 2 PO 4 , 2; Glucose 5.5; and Hepes, 5 (pH 7.4 ) and then perfused with 3% Evans blue in PSS. The kidneys were rapidly removed, placed in ice-cold PSS, and cut into 200-m-thick sections. The tissue slices were incubated for 30 min in 2 ml of a low Ca 2ϩ PSS (0.1 mM CaCl 2 ) containing 1 mg/ml of collagenase (type II, Worthington Biochem, Co.). Preglomerular arteries or arterioles that were filled with Evans blue were identified and collected under a Leica MZ8 stereomicroscope. The dissected arteries were homogenized with a glass homogenizer in ice-cold Hepes buffer, which contains (mM): Na-Hepes, 25; EDTA, 1; phenylmethylsulfonyl fluoride (PMSF), 0.1. After centrifugation of the homogenate at 6000g for 5 min at 4°C, the supernatant containing membrane and cytosolic components, termed homogenate, were frozen in liquid N 2 and stored at Ϫ80°C until used.
Microdissection of renal microvessels. Microdissection was performed as we described previously (Wu et al., 1999) . Sprague-Dawley rats were anesthetized with sodium pentobarbital, and the aorta below left renal artery was isolated and cannulated. After ligating the aorta at a site between the origin of the left and right renal arteries, the left kidney was flushed with 20 ml ice-cold dissection solution which contains (mM): NaCl, 135; KCl, 3; CaCl 2 , 1.5; MgSO 4 , 1; KH 2 PO 4 , 2; Glucose, 5.5; 5; and Hepes, 5 (pH 7.4) . Then the kidney was perfused with 1 ml blue polyethylene beads (diameter ϭ 0.2 m) for visualization of the renal microvessels. Following perfusion, the kidney was removed and cut into 1-to 2-mm-thick sections containing the entire corticomedullary axis. The sections were incubated at 37°C for 30 min in the digestion solution (1 mg/ml collagenase, 1 mg/ml dithiothreitol, and 1 mg/ml bovine albumin in dissection solution) with gentle shaking. During incubation, the samples were bubbled with a 95% O 2 -5% CO 2 mixture. The sections were then rinsed twice with collagenase-free dissection solution and transferred into Petri dishes filled with ice-cold dissection solution containing 0.1 mg/ml trypsin inhibitor and 20 g/ml aprotinin. A petri dish was mounted on the microscope stage and maintained at 4°C during dissection. Microdissection was performed under a Leica MZ8 stereomicroscope with dark-field illumination. The renal vascular and tubule segments and glomeruli were dissected, including arcuate artery (ArA), interlobular artery (IA), afferent arteriole (AA), vasa recta (VR), proximal convoluted tubule (PCT), and medullary collecting duct (mTAL). These vascular and tubular segments were recognized based on their unique feature under microscope as described previously (Wu et al., 1999) . To differentiate the afferent and efferent arterioles, the glomeruli attached to both afferent arterioles and interlobular arteries were chosen, and then the afferent arterioles were dissected from glomeruli and interlobular arteries. Seventy percent of these glomeruli had efferent arterioles attached, which were not attached to Evans blue-stained interlobular arteries. The length of these segments was measured with a calibrated eyepiece micrometer, and the glomeruli (Glm) were counted under microscope. Microdissected vessels, tubules, and glomeruli were lysed in 0.15 M sodium phosphate buffer solution and sonicated for 15 s, three times at 45 W using a microsonicator. The time period for dissection was limited to 1.5 h. In general, 20 glomeruli and 10-to 20-mm vascular and tubular segments were pooled to use as one sample for the analysis of the enzyme activity and assay of protein concentrations. The protein concentrations of the lysate from microdissected vessels, tubules and glomeruli were measured using a Bio-Rad protein assay kit according to the microassay procedures as we described previously (Wu et al., 1999) .
HPLC analysis of cADPR and ADPR. To determine the activity of ADP-ribosyl cyclase, the homogenate (10 g) prepared from bulk-dissected renal vessels and the lysates from microdissected renal microvessels or VSMCs were incubated with 1 mM nicotinamide guanine dinucleotide (NGD) at 37°C for 30 min in Hepes buffer (pH 7.4). NGD was used as a substrate to determine ADP-ribosyl cyclase activity, because this enzyme converts NGD into cGDPR, but unlike cADPR, cGDPR may not be hydrolyzed by cADPR hydrolase (Graeff et al., 1994) . Therefore, the conversion rate of NGD into cGDPR more accurately represented the activity of ADP-ribosyl cyclase in the tissue. The reaction was terminated by removal of protein from the reaction mixtures with Microcon-30 ultrafilter (AMICON) by centrifuging at 3000g at 4°C.
A fluorescent product of ADP-ribosyl cyclase, cGDPR was separated by HPLC and detected with a Hewlett Packard 1046A fluorometer. The excitation wavelength was set at 300 nm, and the emission wavelength was 410 nm.
To determine the hydrolysis of cADPR, the homogenates or lysates of renal vessels were incubated with 1 mM cADPR at 37°C for 30 min, and the products were chromatographed and analyzed using a Hewlett Packard HPLC system with a 1040A photodiode array detector. The column effluent was monitored at 254 nm.
The HPLC system consisted of two Model 110B solvent delivery modules, a 421A controller (Beckman, Berkeley, CA), and a 1040A photodiode array detector or a fluorometric detector with a 20-l flow cell (Hewlett Packard, Avondale, PA). Nucleotides were separated and analyzed in a 3-m Supelcosil LC-18 column (4.6 ϫ 150 mm) with a 5-m Supelcosil LC-18 (4.6 ϫ 20-mm) guard column (Supelco, Bellefonte, BA). The injection volume was 20 l. For cGDPR, the mobile phase consisted of 0.15 M ammonium acetate (pH 5.5) containing 5% methanol (Buffer A) or 50% methanol (Buffer B). For ADPR, the mobile phase consisted of 10 mM potassium dihydrogen phosphate (pH 5.5) containing 5 mM tetrabutylammonium dihydrogen sulfate and 5% acetonitrile (buffer A) and 50% acetonitrile (buffer B). The gradient started from 5% of buffer B, to 30% of buffer B in 25 min, and then up to 50% buffer B in 1 min and continued for 9 min. The flow rate was 0.8 ml/min. The chromatogram was monitored using a fluorescence detector or UV detector as indicated above. Peak identities were confirmed by the retention times and absorption spectra (taken during the peak elution) as compared to the synthetic standards. Data were collected and analyzed by a Chemstation (Hewlett-Packard). Quantitative measurements were performed by comparison of known concentration of standards. All these HPLC methods and protocols were validated in our previous studies (Geiger et al., 2000; Li et al., 1998; Yu et al., 1998) .
[Ca 2؉ ] i assay in renal arterial smooth muscle cells. Arterial smooth muscle cells were enzymatically dissociated from microdissected renal interlobular and afferent arterioles (Ͻ100 m) as we described previously (Zou et al., 1996a,b) . A calcium-sensitive fluorophore, fura 2-AM (Molecular Probes, Eugene, OR) was used for monitoring [Ca 2ϩ ] i (Tsien, 1989) . Freshly dissociated renal arterial smooth muscle cells on poly-dlysine-coated glass coverslips were washed using Hanks' buffer, which contains (mM): NaCl, 130; KCl, 5.4; Hepes, 5.5; Glucose, 5.5; CaCl 2 , 1.25; and MgCl 2 , 1; and incubated with 5 M fura 2-AM at 37°C for 30 min. The coverslip was mounted on a perfusion chamber and then on the stage of an inverted microscope (Nikon Diaphot). The cells were incubated with Hanks' buffer for 20 min at room temperature to allow for complete deesterification of intracellular fura-2, and the ratio of fura-2 emissions when excited at 340 and 380 nm (F 340 /F 380 ) was monitored by using a fluorescence microscopic spectrometry system (PTI). [Ca 2ϩ ] i was calculated using [ (Cornfield et al., 1994; Tsien, 1989) . Direct measurement of calcium release from sarcoplasmic reticulum (SR). Renal arterial smooth muscle cells on coverslips were first equilibrated with Hanks' buffer for 20 min and then washed and incubated with 5 M fura-2-AM at 37°C for 30 min. The coverslip was mounted on a perfusion chamber and then on the stage of an inverted microscope. The cells were permeabilized with 10 M ␤-escin for 3-5 min in a pCa 9.0 solution and washed for 2 min to remove ␤-escin as described previously (Kannan et al., 1996; Yu et al., 1998) . Permeabilized cells were incubated with pCa 6.0 solution for 10 -20 min to load Ca 2ϩ into the SR. Using a fluorescence microscopic spectrometry system, SR Ca 2ϩ release was monitored when cADPR (10 M, Calbiochem, CA) was added. To examine the effect of CICR inhibition on cADPR-induced Ca 2ϩ release response, tetracaine (20 M) was used to pretreat the cells. Doses for cADPR and tetracaine used in the present study were demonstrated to effectively alter Ca 2ϩ release in other tissues by previous studies in our laboratory and by others (Csernoch et al., 1999; Kannan et al., 1996; Yu et al., 1998; Overend et al., 1997) . The fluorescence intensity of intracellular fura-2 was determined and recorded when excited at 340 and 380 nm, and Ca 2ϩ release was indicated by the ratio of F 340 /F 380 . This Ca 2ϩ release response to cADPR was confirmed to be IP 3 independent, since it was blocked by cADPR antagonist, 8-Br-cADPR, but not by IP 3 antagonist, heparin (Yu et al., 1998; Li et al., 2000) . As the cells were permeabilized, intracellular [Ca 2ϩ ] might not be calculated (Kannan et al., 1996) .
Isolated and perfused renal arterial preparation. Small renal interlobular arteries (100 -150 m, i.d.) from Sprague-Dawley rats were carefully dissected and stored in ice-cold PSS. Segments of small arteries were mounted on glass pipettes in a water-jacketed perfusion chamber. The small arteries were perfused and bathed with PSS that was equilibrated with a 95% O 2 -5% CO 2 mixture and maintained at 37°C. This arterial preparation has been shown to have an intact endothelium (Geiger et al., 2000; Zou et al., 1996a; . In the present study, we did not check the integrity of the endothelium in each experiment. However, in previous studies and our recent experiments about endothelium-dependent vasodilation, 95% arteries can be isolated and mounted with an intact endothelium, as determined by a vasodilator response to bradykinin (data not shown). After mounting the artery, the outflow cannula was clamped, and the artery was pressurized to 80 mmHg and equilibrated for 1.5 h. Internal diameter of the artery was measured using a video system composed of a stereomicroscope (Leica MZ8, Leica, Switzerland), a CCD camera (KP-MI AU, Hitachi, Japan), a video monitor (VM-1221, Hitachi, Japan), a video measuring apparatus (VIA-170, Boeckeler Instrument, Tucson, AR) and a video printer (UP890 MD, Sony, Japan). The arterial images were recorded continuously with a video cassette recorder (M-674, Toshiba, Japan). The effects of cADPR on arterial diameters were studied by cumulative additions of cADPR (0.1-10 M) into the bath solution.
Statistics. Data are presented as means Ϯ 1 S.E. The significance of differences within and between groups for multiple groups of data was evaluated using an two-way ANOVA followed by a postdoc test (Duncan's multiple range test) and for two groups of data using a Student's t test (SigmaStat, San Rafael, CA). P Ͻ 0.05 was considered statistically significant. Figure 1A shows a representative fluorescent reverse phase-HPLC chromatogram depicting the conversion of NGD into cGDPR in the homogenates of renal arteries. The conversion rate of NGD into cGDPR represented the ADP-ribosyl cyclase activity. Fluorescent cGDPR had a retention time of 2.1 min. As shown in Fig. 1B , the conversion rate of NGD into cGDPR was increased with elevated protein concentrations in the reaction mixtures. The maximal conversion rate of NGD into cGDPR averaged 8.69 Ϯ 2.39 nmol/min/mg protein in these vessels. The degradation product of cADPR, ADPR, was analyzed by HPLC with a UV detector. A representative chromatogram is presented in Fig. 1C . cADPR and ADPR had retention times of 3.1 and 15.8 min, respectively. A protein concentration-dependent increase in the cADPR hydrolase activity was observed when cADPR was incubated with renal arterial homogenate (Fig. 1D) .
RESULTS

Production and hydrolysis of cADPR in the homogenate prepared from intrarenal arteries.
Production of cADPR in microdissected renal microvessels. Compared to the tubule segments (proximal convoluted tubule (PCT) and medullary thick ascending limb (mTAL)), the renal vessels, including microvessels such as interlobular and afferent arterioles, expressed greater ADP-ribosyl cyclase activity. Maximal enzyme activity was found in arcuate arteries. The enzyme activity was much higher in afferent arterioles than in vasa recta. Glomeruli also produced cADPR, and the enzyme activity in glomeruli was similar to the preglomerular arteries and arterioles (Fig. 2) .
Production of cADPR in renal arterial SMCs. When the lysate of renal vascular SMCs was incubated with 1 mM NGD, the conversion rate of NGD into cGDPR was increased in a protein concentration-dependent manner. The relationship between the production of cADPR and protein concentrations in renal vascular SMCs was similar to that in renal arterial homogenate. The maximal conversion rate of NGD into cGDPR averaged 10.97 Ϯ 2.39 nmol/min/mg protein in these SMCs (Fig. 3) .
Effect of cADPR on Ca 2؉ release and intracellular [Ca 2؉ ] in renal arterial SMCs. Figure 4A presents a typical recording depicting Ca 2ϩ release response from the SR of ␤-escin-permeabilized renal arterial smooth muscle cells and the effect of the CICR inhibitor, tetracaine on the SR Ca 2ϩ release induced by cADPR. Addition of cADPR (10 M) produced a rapid Ca 2ϩ release response. In the presence of tetracaine (20 M), the effect of cADPR on the SR Ca 2ϩ release was substantially attenuated. Figure 4B summarizes the Ca 2ϩ release response to cADPR in the absence and presence of tetracaine. cADPR increased the ratio of F 340 / F 380 by 0.53, a 75% increase. In the presence of tetracaine, cADPR-induced Ca 2ϩ release was reduced by 70%.
In fura-2-loaded cells without ␤-escin-permeabilization, cADPR increased [Ca 2ϩ ] i from baseline of 238 to 283 nM, which represents a mild increase in [Ca 2ϩ ] i compared to the permeabilized cells. In contrast to a rapid Ca 2ϩ response in the ␤-escin-permeabilized cells, increase in [Ca 2ϩ ] i in these intact cells occurred 10 -15 min after cADPR was added into the bath. Ca 2ϩ channel blocker, nifedipine (10 M) had no effect on cADPR-induced increase in [Ca 2ϩ ] i . In the presence of tetracaine (20 M), cADPR only elevated [Ca 2ϩ ] i from 172 to 189 nM. The Ca 2ϩ response of tetracaine-pretreated cells to cADPR was reduced by 62%.
Effect of cADPR on renal arterial diameters. Addition of cADPR into the bath solution produced   FIG. 3 . ADP-ribosyl cyclase activity in renal arterial smooth muscle cells (n ϭ 6 rats). The cells were enzymatically dissociated from renal interlobular and afferent arterioles.
FIG. 2.
ADP-ribosyl cyclase activity in the lysate or homogenates of microdissected renal vessels and tubules. These vessel and tubule segments included arcuate artery (ArA, n ϭ 6 rats), interlobular artery (IA, n ϭ 6), afferent arteriole (AA, n ϭ 7), vasa recta (VR, n ϭ 10), proximal convoluted tubule (PCT, n ϭ 6), medullary collecting duct (mTAL, n ϭ 6), and glomeruli (Glm, n ϭ 10). *Indicates significant difference (P Ͻ 0.05) compared with the values obtained from ArA.
time-dependent vasoconstriction. The decrease in arterial diameter reached a plateau 25 min after administration of cADPR. The typical video images of isolated, perfused, and pressurized renal interlobular artery are presented in Fig. 5A . The diameter of this pressurized renal artery was markedly reduced 25 min after cADPR (10 M) was added into the bath, suggesting a vasoconstriction. Pretreatment of the renal artery with tetracaine (20 M) blocked the vasoconstrictor effect of cADPR. Figure  5B summarizes the effects of cADPR on vascular diameter of small renal arteries. Addition of cADPR into the bath produced a concentration-dependent decrease in vascular diameter. The vasoconstrictor effect of cADPR can be completely blocked by tetracaine.
DISCUSSION
In the present study, the enzymatic pathway responsible for the production and metabolism of a novel Ca 2ϩ mobilizing second messenger, cADPR was characterized in the renal vasculature. Using HPLC analysis, we demonstrated that the homogenate pre- pared from preglomerular arteries expressed the activity of ADP-ribosyl cyclase and cADPR hydrolase, suggesting that cADPR is produced and hydrolyzed in these blood vessels. Recent studies have indicated that in a variety of mammalian tissues NAD is converted into cADPR by cyclization via ADP-ribosyl cyclase and cADPR can be hydrolyzed by cADPR hydrolase. The activities of both enzymes determine cADPR concentrations within cells and thereby control intracellular Ca 2ϩ mobilization (Beer et al., 1995b; Galione et al., 1993; Koshiyama et al., 1991; Lee, 1994; Lee and Aarhus, 1993; Takasawa et al., 1993; . Therefore, demonstration of ADP-ribosyl cyclase and cADPR hydrolase in the renal vasculature suggests the presence of cADPR-mediated Ca 2ϩ signaling pathway.
To determine the localization of cADPR production, renal microvessels and tubules were microdissected along the renal nephron for the analysis of ADP-ribosyl cyclase activity. In the pre-and postglomerular microvessels including afferent arterioles and vasa recta, the production of cADPR was detected. Preglomerular arteries or arterioles exhibited a greater activity of ADP-ribosyl cyclase compared to postglomerular vasa recta. In tubule segments such as proximal convoluted tubules and medullary thick ascending limb, ADP-ribosyl cyclase activity was minimal. It appears that the vascular smooth muscle expressed great activity of ADP-ribosyl cyclase since preglomerular arteries have more smooth muscle cells compared to vasa recta and tubule segments. This view is supported by a direct measurement of cADPR production in arterial smooth muscle cells dissociated from interlobular and afferent arterioles. The activity of ADP-ribosyl cyclase was found to be comparable in these arterial smooth muscle cells to whole vascular homogenates. In previous studies, we also demonstrated that cultured coronary vascular smooth muscle cells produced more cADPR compared to endothelial cells Yu et al., 1998) . Given the role that cADPR plays in the control of intracellular Ca 2ϩ mobilization, enriched ADP-ribosyl cyclase activity in vascular smooth muscle cells may be of importance in the control of vascular tone in renal arteries or arterioles through cADPR-mediated action on [Ca 2ϩ ] i . To test this hypothesis, we determined the effects of cADPR to stimulate Ca 2ϩ release from intracellular stores and to increase [Ca 2ϩ ] i in single vascular smooth muscle cells with the use of fluorescent microscopic spectrometry. Using ␤-escin permeabilized arterial smooth muscle cells isolated from renal interlobular and afferent arterioles, the direct action of cADPR to stimulate Ca 2ϩ release was observed. As described in previous studies using ␤-escin permeabilized porcine coronary arterial smooth muscle cells, a rapid increase in Ca 2ϩ signal induced by cADPR represents Ca 2ϩ release from the sarcoplasmic reticulum (Kannan et al., 1996) . Since IP 3 receptor inhibitor, heparin had no effect on this Ca 2ϩ release response, it seems that the effect of cADPR is not associated with IP 3 signaling pathway in these vascular smooth muscle cells. This is in agreement with other reports indicating that cADPR mobilizes intracellular Ca 2ϩ through a mechanism independent of IP 3 (Lee, 1993 (Lee, , 1994 Lee et al., 1994) .
The present study also explored the mechanism by which cADPR stimulates Ca 2ϩ release from sarcoplasmic reticulum in renal arterial smooth muscle cells. There is accumulating evidence indicating that cADPR may mobilize intracellular Ca 2ϩ through Ca 2ϩ -induced Ca 2ϩ release (CICR) in nonvascular tissues. It has been demonstrated that procaine and ruthenium red, the CICR blockers selectively inhibit the cADPRinduced Ca 2ϩ release and that caffeine and Ca 2ϩ as the agonists of CICR dramatically potentiated Ca 2ϩ -releasing activity of cADPR (Galione et al., 1991; Lee, 1993 Lee, , 1994 . In the present study, tetracaine, a specific CICR inhibitor (Csernoch et al., 1999; Overend et al., 1997) was used to address the association of CICR with cADPR-induced Ca 2ϩ release. The results showed that in ␤-escin-permeabilized renal arterial smooth muscle cells tetracaine markedly decreased cADPR-induced Ca 2ϩ release response, suggesting that CICR contributes to the actions of cADPR in these arterial smooth muscle cells.
cADPR-sensitive CICR has been shown to play an important role in excitation-contraction coupling in cardiac muscle and in the coupling between Ca 2ϩ influx and intracellular Ca 2ϩ release in the neurons (Empson and Galione, 1997; Galione et al., 1998; Rakovic et al., 1996) . In vascular smooth muscle, CICR may also participate in the regulation of intracellular [Ca 2ϩ ] and vascular tone (Berridge, 1997; Ito et al., 1991; Kamishima and McCarron, 1997; Knot et al., 1998 (Berridge, 1997) . In addition, the entry of Ca 2ϩ through voltage-operating channels may be amplified by CICR, resulting in a global Ca 2ϩ increase throughout the cytoplasma and nucleus and consequently producing vasoconstriction (Berridge, 1994 (Berridge, , 1997 . Considering the association of cADPR and CICR, we propose that cADPR may play a critical role in the control of the resting tone and in the development of vasoconstriction induced by different stimuli such as activation of voltage-operating Ca 2ϩ channels in the renal arteries or arterioles.
Using isolated, perfused and pressurized renal interlobular arterial preparation, cADPR was found to decrease arterial diameters when added into the bath solution, suggesting a vasoconstrictor response to this nucleotide. Since cADPR has been considered as an intracellular second messenger, it remains unknown how this nucleotide produces vasoconstriction and how it enters into the cells when administrated exogenously. However, there are three lines of evidence indicating that cADPR induces vasoconstriction in this arterial preparation through increases in [Ca 2ϩ ] i or CICR mechanism. First, cADPR was found to increase [Ca 2ϩ ] i in intact arterial smooth muscle cells when added into the bath solution by direct measurement with the single cell fluorescent spectrometry. The increase in intracellular Ca 2ϩ may activate arterial vasoconstriction. Second, tetracaine, a CICR inhibitor substantially blocked the increase in [Ca 2ϩ ] i and vasoconstrictor response to exogenously administrated cADPR. This suggests that the vasoconstrictor effect of cADPR is associated with CICR mechanism. Finally, a time delay of both increase in intracellular Ca 2ϩ response and vasoconstriction was observed when cADPR was added into the bath solution, suggesting that a time period is needed for cADPR to enter into the cells. In regard to the mechanism by which cADPR enters into the cells, recent studies indicated that the NAD/cADPR transporters on the cell membrane may mediate the uptake of these nucleotides (Zocchi et al., 1999) . However, the physiological significance of this cADPR transport system in intracellular Ca 2ϩ signaling remains to be further elucidated.
In summary, we demonstrate that vascular smooth muscle in renal vasculature, including afferent arterioles and vasa recta, is capable to produce and hydrolyze cADPR. cADPR stimulates Ca 2ϩ release from the sarcoplasmic reticulum of vascular smooth muscle cells and thereby produces renal vasoconstriction through CICR mechanism. We conclude that an enzymatic pathway for cADPR production and metabolism is present in renal vascular smooth muscle and that cADPR-mediated Ca 2ϩ signaling may importantly contribute to the control of renal vascular tone through CICR.
